ArticleCancers2025

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival.

Elisabetta Perrone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.